These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 23651793)

  • 41. Pharmacokinetic and safety profile of rupatadine when coadministered with azithromycin at steady-state levels: a randomized, open-label, two-way, crossover, Phase I study.
    Solans A; Izquierdo I; Donado E; Antonijoan R; Peña J; Nadal T; Carbó ML; Merlos M; Barbanoj M
    Clin Ther; 2008 Sep; 30(9):1639-50. PubMed ID: 18840369
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pharmacokinetic and pharmacodynamic properties of the calcimimetic agent cinacalcet (KRN1493) in healthy male Korean subjects: a randomized, open-label, single ascending-dose, parallel-group study.
    Lee S; Gu N; Kim BH; Lim KS; Shin SG; Jang IJ; Yu KS
    Clin Ther; 2012 May; 34(5):1160-9. PubMed ID: 22503212
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacokinetics and pharmacodynamics of epoetin delta in two studies in healthy volunteers and two studies in patients with chronic kidney disease.
    Smith WB; Dowell JA; Pratt RD
    Clin Ther; 2007 Jul; 29(7):1368-80. PubMed ID: 17825688
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A randomised, two-period, cross-over, open-label study to evaluate the pharmacokinetic profiles of single doses of two different flurbiprofen 8.75-mg lozenges in healthy volunteers.
    Matzneller P; Burian A; Martin W; Annoni O; Lauro V; Tacchi R; Brunner M; Zeitlinger M
    Pharmacology; 2012; 89(3-4):188-91. PubMed ID: 22433300
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pharmacokinetic properties of mirabegron, a β3-adrenoceptor agonist: results from two phase I, randomized, multiple-dose studies in healthy young and elderly men and women.
    Krauwinkel W; van Dijk J; Schaddelee M; Eltink C; Meijer J; Strabach G; van Marle S; Kerbusch V; van Gelderen M
    Clin Ther; 2012 Oct; 34(10):2144-60. PubMed ID: 23063375
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Relative bioavailability of the fentanyl effervescent buccal tablet (FEBT) 1,080 pg versus oral transmucosal fentanyl citrate 1,600 pg and dose proportionality of FEBT 270 to 1,300 microg: a single-dose, randomized, open-label, three-period study in healthy adult volunteers.
    Darwish M; Tempero K; Kirby M; Thompson J
    Clin Ther; 2006 May; 28(5):715-24. PubMed ID: 16861093
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Single-dose bioavailability of levetiracetam intravenous infusion relative to oral tablets and multiple-dose pharmacokinetics and tolerability of levetiracetam intravenous infusion compared with placebo in healthy subjects.
    Ramael S; De Smedt F; Toublanc N; Otoul C; Boulanger P; Riethuisen JM; Stockis A
    Clin Ther; 2006 May; 28(5):734-44. PubMed ID: 16861095
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparative bioavailability of single-dose methylphenidate from a multilayer-release bead formulation and an osmotic system: a two-way crossover study in healthy young adults.
    Reiz JL; Donnelly GA; Michalko K
    Clin Ther; 2008 Jan; 30(1):59-69. PubMed ID: 18343243
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Inhaled growth hormone (GH) compared with subcutaneous GH in children with GH deficiency: pharmacokinetics, pharmacodynamics, and safety.
    Walvoord EC; de la Peña A; Park S; Silverman B; Cuttler L; Rose SR; Cutler G; Drop S; Chipman JJ
    J Clin Endocrinol Metab; 2009 Jun; 94(6):2052-9. PubMed ID: 19336514
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Evaluation of the absolute bioavailability of pegylated interferon alfa-2a after subcutaneous administration to healthy male volunteers: an open-label, randomized, parallel-group study.
    Brennan BJ; Xu ZX; Grippo JF
    Clin Ther; 2012 Sep; 34(9):1883-91. PubMed ID: 22858176
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pharmacokinetic bridging approach for developing biologics-delivery devices: a case study with a golimumab autoinjector.
    Xu Z; Marciniak SJ; Frederick B; Kim L; Zhuang Y; Davis HM; Zhou H
    Clin Ther; 2015 Feb; 37(2):427-38. PubMed ID: 25438720
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effects of food intake on the pharmacokinetic properties of dalcetrapib: findings from three phase I, single-dose crossover studies in healthy volunteers.
    Derks M; Kawamura H; Abt M; Meneses-Lorente G; Phelan M; Ishikawa T
    Clin Ther; 2011 Jun; 33(6):754-65. PubMed ID: 21704240
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Single-dose relative bioavailability of a new quetiapine fumarate extended-release formulation: a postprandial, randomized, open-label, two-period crossover study in healthy Uruguayan volunteers.
    Estevez-Carrizo FE; Parrillo S; Ercoli MC; Estevez-Parrillo FT
    Clin Ther; 2011 Jun; 33(6):738-45. PubMed ID: 21704238
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Absolute bioavailability of intranasal fluticasone furoate in healthy subjects.
    Allen A; Down G; Newland A; Reynard K; Rousell V; Salmon E; Scott R
    Clin Ther; 2007 Jul; 29(7):1415-20. PubMed ID: 17825692
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Relative bioavailability and pharmacokinetics of a new sibutramine formulation in healthy male subjects: a randomized, open-label, two-period, comparative crossover study.
    Park JY; Kim KA; Park PW; Suh KH; Lee GS
    Clin Ther; 2004 Dec; 26(12):2092-101. PubMed ID: 15823773
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparative pharmacokinetics, safety, and tolerability after subcutaneous administration of recombinant human erythropoietin formulated with different stabilizers.
    Cheung WK; Natarajan J; Sanders M; Vercammen E
    Biopharm Drug Dispos; 2000 Sep; 21(6):211-9. PubMed ID: 11304719
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Absolute Bioavailability and Pharmacokinetic Comparability of Sirukumab Following Subcutaneous Administration by a Prefilled Syringe or an Autoinjector.
    Zhuang Y; de Vries DE; Marciniak SJ; Liu H; Zhou H; Davis HM; Leon F; Raible D; Xu Z
    Clin Pharmacol Drug Dev; 2017 Nov; 6(6):570-576. PubMed ID: 28052588
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Tolerability of High-Volume Subcutaneous Injections of a Viscous Placebo Buffer: A Randomized, Crossover Study in Healthy Subjects.
    Dias C; Abosaleem B; Crispino C; Gao B; Shaywitz A
    AAPS PharmSciTech; 2015 Oct; 16(5):1101-7. PubMed ID: 25693652
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Relative Bioavailability of a Single Dose of Belimumab Administered Subcutaneously by Prefilled Syringe or Autoinjector in Healthy Subjects.
    Struemper H; Murtaugh T; Gilbert J; Barton ME; Fire J; Groark J; Fox NL; Roth D; Gordon D
    Clin Pharmacol Drug Dev; 2016 May; 5(3):208-15. PubMed ID: 27163500
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Antagon/Orgalutran). Part I. Absolute bioavailability of 0.25 mg of ganirelix after a single subcutaneous injection in healthy female volunteers.
    Oberyé JJ; Mannaerts BM; Kleijn HJ; Timmer CJ
    Fertil Steril; 1999 Dec; 72(6):1001-5. PubMed ID: 10593371
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.